Jacco D. H.
- Country
- The Netherlands
- Department
- Internal Oncology
Research Overview
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
- Randomized Phase II/III Study of Cabozantinib Maintenance Versus Best Supportive Care in Osteosarcoma Patients After First‑Line Chemotherapy (FOSTER‑CabOS)
- Evaluation of AZD5863 and Tocilizumab in Advanced or Metastatic Solid Tumors: A Phase I/II Dose Escalation and Expansion Study
Data & Insights
Has run more than one trial at 39 of 150 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating advanced and metastatic solid tumors, with particular emphasis on developing innovative therapeutic approaches for challenging cancer types.
- Sarcoma Research
- Gastrointestinal Cancers
- Conventional Chondrosarcoma
Their expertise extends to SDH-deficient solid tumors and gastrointestinal stromal tumors (GIST).
Gastroesophageal Studies
The investigator conducts research in HER2-positive advanced gastric and esophageal cancers, exploring combination therapy approaches.
- Gastroesophageal Adenocarcinoma
- Advanced Malignancies
- Targeted Therapies
Their work includes evaluation of novel therapeutic combinations for unresectable locally advanced and recurrent cancers.
Innovative Treatments
The investigator focuses on developing treatments for CLDN18.2-expressing tumors and exploring novel therapeutic combinations.
- Combination Therapies
- Immunotherapy Approaches
- Molecular Targeted Treatments
Their research includes evaluation of safety and tolerability profiles of emerging cancer therapeutics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.